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Abstract
Leukemia is a type of cancer of the body’s blood-forming tissues, including the bone
marrow and the lymphatic system. Treatments for leukemia are complex, depending
upon the type of leukemia and other factors. Acute promyelocytic leukemia (APL) is
a distinct subtype of acute myeloid leukemia (AML) and accounts for approximately
10-15% of all cases of AML in adults. Arsenic and its compounds are widely distribut‐
ed in the environment and have been used medicinally for over 2,000 years. In fact,
investigators from China and the USA have demonstrated that treatment with ATO
(As2O3, AsIII) results in complete remission in 90% of relapsed APL patients since
mid-1990s. Moreover, As2S2 or As4S4, also known as realgar, has been gaining increasing
attention and is traditionally used to treat certain types of hematological disorders
including chronic myeloid leukemia (CML), AML, myelodysplastic syndrome (MDS)
and MDS/AML in China. In this chapter, we first highlight the pharmacokinetics of
ATO and realgar in leukemia patients and/or healthy volunteer. We will further
summarize the detailed mechanisms underlying the cytocidal effects of these arsenic
compounds. We also provide detailed insight into potential future clinical applica‐
tion of those promising candidates endowed with potent antitumor activities in view
of combination with arsenic compounds.
Keywords: leukemia, arsenic trioxide, realgar, combination therapy, naturally de‐
rived substances
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1. Introduction
Leukemia is a type of cancer of the body’s blood-forming tissues, including the bone marrow
(BM) and the lymphatic system. Treatments for leukemia are complex, depending on the type
of leukemia and other factors. At present, treatment may include some combination of
chemotherapy, radiation therapy, targeted therapy, and hematopoietic stem cell transplanta‐
tion, in addition to supportive care and palliative care as needed.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML)
and accounts for approximately 10–15% of all cases of AML in adults. Morphologically, it is
identified as AML–M3 by the French–American–British classification. Cytogenetically, APL is
characterized by a balanced reciprocal translocation between chromosomes 15 and 17,
generating a promyelocytic leukemia (PML)/retinoic acid receptor α (RARα) fusion gene,
which is thought to play a central role in the initiation of leukemogenesis [1–4]. The oncogenic
fusion protein PML-RARα has been demonstrated to recruit corepressor (CoR) complexes
containing nuclear receptor CoRs, histone deacetylases (HDACs), resulting in myeloid
differentiation arrest observed in APL [5, 6]. An introduction of all-trans retinoic acid (ATRA)
since 1986 has dramatically improved the outcome of treatment of this disease [5]. It has been
reported that ATRA induces differentiation of APL cells through not only dissociating CoRs
from the PML-RARα oncoprotein but also recruiting coactivators that possess histone
acetylase activity [5–7]. For detailed mechanisms underlying the efficacy of ATRA, please refer
to some excellent research and review articles [6, 8–11]. In fact, in 90% of de novo APL patients,
administration of ATRA induces differentiation of leukemic blasts and clinical remission, and
70% of them have been cured by ATRA administration in combination with chemotherapy [4,
6, 12]. Due to its good clinical outcomes, ATRA is used as a first-line administration for de
novo APL patients. Nevertheless, the remaining 30% of patients relapse and often become
resistant to this conventional treatment [4, 6, 12].
Arsenic and its compounds are widely distributed in the environment and exist in organic and
inorganic forms. There are three inorganic forms of arsenic: yellow arsenic (As2S3, also known
as orpiment and Cihuang “female yellow” in China); red arsenic (As2S2 or As4S4, also known
as realgar and Xionghuang“male yellow” in China); and white arsenic or ATO (As2O3, AsIII),
which is made by burning realgar or orpiment [6]. Although a well-known poison, arsenic has
been used medicinally for over 2 000 years. Since the mid-1990s, investigators from China and
the USA have demonstrated that treatment with ATO results in complete remission in 90% of
relapsed APL patients [4, 13–15]. From then on, a dramatic clinical efficacy of ATO-based
regimens against APL has been reported around the world. An impressive drug efficacy
against APL led to its approval in the USA and in Europe under the brand name Trisenox for
“the induction of remission and consolidation in patients with APL whose conditions are
refractory to, or who have relapsed from retinoid and anthracycline chemotherapy, and whose
APL is characterized by the presence of the t(15:17) translocation or PML-RARα gene expres‐
sion” [13]. Moreover, As2S2 as another important arsenic compound has been gaining increas‐
ing attention and traditionally used to treat certain types of hematological disorders, including
chronic myeloid leukemia (CML), AML, myelodysplastic syndrome (MDS) and MDS/AML in
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China [16–18]. Although realgar has not yet been approved by the U.S. Food and Drug
Administration (FDA) and other major countries for clinical use, it has become another
research for focus following ATO due to its good therapeutic efficacy and perceived low
toxicity [19, 20].
In this chapter, we first highlight the pharmacokinetics of ATO and realgar in leukemia patients
and/or a healthy volunteer. We will further summarize the detailed mechanisms underlying
the cytocidal effects of these arsenic compounds. We also provide detailed insight into
potential future clinical applications of those promising candidates endowed with potent
antitumor activities in view of combination with arsenic compounds.
2. Pharmacokinetics of arsenic compounds in leukemia patients
2.1. Pharmacokinetic studies of ATO in Peripheral Blood (PB)
It has been established that biomethylation, which primarily occurred in the liver [21, 22], is a
major metabolic pathway for inorganic arsenic in human and many animal species [23], by
which arsenic undergoes metabolic conversion by the reduction of AsV to AsIII with subsequent
methylation, yielding monomethylated and dimethylated metabolites [24, 25]. A postulated
metabolic pathway is as follows: AsV → AsIII → methylarsonic acid (MAsV) → methylarsonous
acid (MAsIII) → dimethylarsinic acid (DMAsV) → dimethylarsinous acid (DMAsIII) (Figure 1).
It has been demonstrated that, following arsenic exposure, 40–60% of arsenic intake is
eliminated through urine. The standard profile of urinary arsenic in human is comprised of
10–30% inorganic arsenic, 10–20% monomethylated arsenic (MAs: MAIII + MAV), and 60–80%
dimethylated arsenic (DMAs: DMAIII + DMAV) [26, 27].
Figure 1. Postulated pathways of the biotransformation of arsenic in mammalian systems. Biomethylation, which pri‐
marily occurs in the liver, is a major metabolic pathway for inorganic arsenic in human and many animal species. In
human, dimethylarsinous acid (DMAsIII) and dimethylarsinic acid (DMAsV) appear to be the end products of this path‐
way [133]. In the pathway, arsenate reductases, such as the omega isoform of glutathione S-transferase (GSTO) and
purine nucleoside phosphorylase (PNP), catalyse the reduction of arsenate species [4, 22]. Human arsenic (+ 3 oxida‐
tion state) methyltransferase (AS3MT) catalyse the methylation of arsenite [4, 22]. S-adenosylmethionine (SAM) is the
methyl donor [4, 22].
In order to provide an effective treatment protocol for individual APL patients, detailed studies
have been conducted on the pharmacokinetics of AsIII in APL patients using biological samples
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such as peripheral blood (PB), cerebrospinal fluid (CSF), BM, and urine [14, 28–31]. Compared
with a limited understanding of metabolic profiles of realgar and its pharmacokinetics, many
detailed systematic analyses of the metabolites of ATO in blood cells and plasma of APL
patients have been performed. In this regard, by using high-performance liquid chromatog‐
raphy (HPLC)/inductively coupled plasma mass spectrometry (ICP-MS), we have conducted
studies on the total arsenic and speciation of ATO metabolites in an APL patient when 0.15
mg/kg/day was infused. Blood samples were obtained from the patient at various time points
after remission induction therapy and during consolidation therapy [31]. Of note, biological
samples, such as blood and urine, contain much higher concentrations of chloride ion, which
interferes with arsenic detection at m/z 75 due to the formation of argon chloride (40Ar35Cl+: m/
z 75) in argon plasma [28, 32]. Therefore, arsenic was detected as the adduct ion of 75As16O+ (m/
z 91), which is produced by the oxidization of arsenic in the oxygen atmosphere with the
dynamic reaction cell techniques [31].
We first demonstrated that, in all blood samples collected either after the remission induction
therapy or during the consolidation therapy, approximately 80–90% of the total arsenic in the
blood samples was observed in the blood cells, suggesting that most of the blood arsenic is
bound to hemoglobin [31]. These results are in good agreement with a previous report showing
that 90% of blood arsenic is bound to hemoglobin [33]. These findings suggest that careful
attention should be paid to profiles of total arsenic in blood cells and consequently provide
valuable insight into clinical applications of AsIII. We further clarified that, during the drug
withdraw period, the amount of AsV in plasma was more readily eliminated among all arsenic
metabolites [31], as reported by other groups [32, 34]. We also demonstrated that AsIII
concentrations in plasma initially declined more quickly than those of MAsV and DMAsV [31].
These results suggest that methylated metabolites (MAsV and DMAsV) are major metabolites
in plasma and are similar to those reported by other groups [23–25]. Furthermore, we dem‐
onstrated that the concentrations of methylated metabolites (MAsV and DMAsV) as well as
inorganic arsenic (AsIII and AsV) in plasma increased with multiple administration during the
consolidation therapy period [31]. In comparison, Fujisawa et al. demonstrated no increase in
the maximum concentrations of inorganic arsenic (AsIII and AsV) despite multiple administra‐
tions, suggesting that inorganic arsenic plasma may reach a steady state after multiple
administration [28]. It is noteworthy that only one of the 14 patients enrolled in the study of
Fujisawa et al. was in the first relapse, and the remaining patients were in the second to fifth
relapse [28]. In contrast, the patient in our study was in the first relapse [31]. Although the
exact reason for the above-mentioned apparent differences in the profiles of the concentrations
of inorganic arsenic (AsIII and AsV) in the plasma of APL patients is not clear, the differences
in patient characteristics may explain the discrepancy in the concentrations of inorganic
arsenic. These results also suggest that understanding the differences in metabolism among
patients is very useful for providing an effective treatment protocol for individual patients
with leukemia.
2.2. Pharmacokinetic studies of ATO in the CSF
Although the central nervous system (CNS) relapse of APL occurs in 1–5% of patients, the
optimal therapy for this case remains unclear [35, 36]. Fortunately, several clinical data have
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demonstrated that ATO seems to be capable of crossing the blood–brain barrier in humans
and can be considered as an effective treatment strategy for the CNS relapse of APL [37–40].
We have recently determined the total arsenic and speciation of ATO metabolites in the CSF
and PB plasma samples from three patients with APL who were treated with intravenous ATO
as salvage therapy [0.15 mg/kg/day ATO + intrathecal chemotherapy (methotrexate + cytosine
arabinoside + prednisolone)] [29]. In this study, PB was collected before and after the infusion,
and the CSF was collected after the infusion, respectively. Furthermore, in order to prepare
samples for arsenic speciation, the PB plasma was ultrafiltered with a 10-kDa molecular mass
cutoff. The filtrates were thus defined as low-molecular-weight fraction (LMW-F) and
subjected to arsenic speciation analysis. The remains trapped in filters were defined as high-
molecular-weight fraction (HMW-F) and subjected to total arsenic determination [29]. We first
demonstrated that not only inorganic arsenic (AsIII and AsV) but also methylated arsenic
metabolites (MAsV and DMAsV) existed in the CSF and that the total CSF arsenic concentrations
ranged from 148 nM to 250 nM (mean: 199 nM) [29]. It has been demonstrated that ATO exerts
a dual effect on APL cells; that is, ATO induces apoptosis at relatively high concentrations,
ranging from 1 μM to 2 μM, whereas trends to promote differentiation of APL cells at low
concentrations range from 0.1 μM to 0.5 μM [4, 6, 41]. Therefore, the beneficial effects of arsenic
on the CNS relapse of APL patients might be attributed to its differentiation induction, rather
than apoptosis induction. Furthermore, we found that the total PB plasma arsenic concentra‐
tion is about twice of the sum of the amount of each arsenic metabolite present in LMW-F [29].
We also demonstrated that the total arsenic concentration in HMW-F accounted for approxi‐
mately 50% of the total PB plasma arsenic concentration, suggesting that considerable amounts
of arsenic species exist in clinical samples as a protein-bound complex.
Similar to previous reports showing that arsenic concentrations in the CSF were about 10% of
those in whole blood or plasma [38, 40], we also demonstrated that the arsenic concentrations
of the CSF were 8–17% of the plasma levels [29]. Taken together, it is possible to use a combi‐
nation of arsenic with other chemotherapeutics to achieve a favorable clinical outcome in APL
patients with CNS relapse, although a further larger scale randomized study must be con‐
ducted to reach a firm conclusion. It is noteworthy that Meng et al. have developed a non-
invasive method via a concomitant with 20% mannitol intravenous bolus injection to help ATO
enter into the CNS [42]. Their regimens include 125 ml of 20% mannitol bolus through the
medial cubital vein at the rate of 12 ± 30 ml/min, followed with 250 ml of mixed solution
(including 20% mannitol and ATO 0.08 mg/kg/day) through intravenous infusion at the rate
of 6 ml/min, followed by ATO 0.08 mg/kg/day + 5% glucose 250-ml infusion at the rate of 0.5
ml/min in the total dosage of ATO (0.16 mg/kg/day) [42]. Compared with the general ATO
intravenous infusion, the mannitol-assisted ATO penetration followed by the slow-speed
continuous ATO intravenous infusion can not only increase the elemental arsenic concentra‐
tion in the CNS but also keep the plasma arsenic at prolonged effective therapeutic levels
without remarkable plasma arsenic peak. Therefore, the non-invasive method was supposed
to be more beneficial to the CNS relapse of APL and increase the prevention and treatment
efficiency of APL marrow relapse, as well as less side effects to normal tissues [42]. The same
group has recently extended the application of the non-invasive method to additional patients
[43]. They demonstrated that, in 16 of the 17 patients examined, abnormal blasts/promyelo‐
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cytes from the CSF were eliminated in 18 to 32 days (median: 24 days) after the start of induction
treatment and that all the patients tolerated the induction well. Importantly, there were no
complaints of side effects associated with the use of mannitol [43]. Of note, over the course of
the entire induction treatment process, the concentrations of arsenic in the blood and CSF were
fairly stable in each patient. For each individual, the arsenic level in the CSF was ~99.7% of
those in the paired blood samples, although the arsenic levels in different individuals were
highly variable in the blood and CSF [43].
2.3. Pharmacokinetic studies of ATO in the BM
Although an initial report demonstrated that the total arsenic concentrations in the plasma of
a BM sample from five relapsed APL patients were close to levels for differentiation induction,
the analysis was conducted for the BM sample collected at only one collection time point [44].
Moreover, despite the fact that BM is a vital site for regulating the production of blood cells,
no speciation analysis of arsenicals in the BM from APL patients undergoing long-term
administration of ATO has been done before. In this regard, in order to gain more detailed
information on the distribution of arsenic, we have recently investigated, for the first time, the
arsenic speciation in the plasma of the BM and compared the arsenic speciation profiles
between the PB and BM collected before and after the start of administration of 0.15-
mg/kg/day ATO [30]. In this study, we first demonstrated a time-dependent increase of the
total arsenic concentrations in the BM plasma, which was similar to that in the PB plasma.
Furthermore, the total arsenic concentration levels tended to be higher in the BM plasma than
those in the PB plasma, raising clinical concerns and inspiring us to unravel the detailed
information on the distribution of arsenic as well as its speciation in these biological samples
[30]. In this study, the concentrations of MAsV and DMAsV substantially increased after the
start of administration, whereas those of AsIII were still kept at a low level until day 10, followed
by a substantial increase from day 14 after the start of administration. As mentioned in Section
2.1, we have previously demonstrated that the PB plasma concentrations of both methylated
arsenic metabolites (MAsV and DMAsV) and inorganic arsenic (AsIII and AsV) remarkably
increased after the start of administration in a Japanese APL patient undergoing consolidation
therapy [31]. Compared with the APL patient in our previous study [31], the patient enrolled
in this study appeared to have relatively higher metabolic efficiency, probably due to her
relatively young age or without clinical complications. Collectively, our findings suggest that
the efficiency of drug metabolism is obviously different in individual patients with different
backgrounds, such as age range, with or without organ failure or disseminated intravascular
coagulation (DIC), which, in turn, affect clinical outcomes and appearance of side effects. Of
note, a close similarity of the arsenic speciation profiles between the PB and BM plasma was
observed throughout the remission induction therapy, suggesting for the first time that the
arsenic speciation analysis of the PB plasma could be predicative for BM speciation without
applying BM aspiration [30]. Investigation of the total amount of arsenic in HMW-F trapped
in a 10-kDa molecular mass cutoff filters further demonstrated that arsenic concentrations were
much higher in the BM plasma than those in the PB plasma. One important biological effect
of arsenic has been suggested to be mediated by reaction with closely spaced cysteine residues
on a critical cell protein [45]. Several proteins such as tubulin, thioredoxin reductase, human
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arsenic methyltransferase (AS3MT, responsible for arsenic methylation) with a high cysteine
content, and accessible thiol group are candidates for interactions with arsenic [4, 46]. In fact,
arsenic bound to high molecular weight proteins (MW > 10-kDa) has been detected in livers
and kidneys in rats after an intravenous injection of arsenite [47]. In view of the vital role of
the BM microenvironment in maintaining the homeostasis of hematopoietic system, we
assumed that a higher amount of proteins (MW > 10-KDa)-bound arsenic complex contributes
to the protection effect from the attack of free arsenic species. Likewise, patients with low-
proteinemia besides liver and/or renal dysfunctions might frequently develop arsenic-
mediated side effects. Understandably, further investigation of the detailed information about
these proteins is needed.
2.4. Pharmacokinetic studies of ATO in urine
The pharmacokinetic studies in APL patients have been well discussed by using urine samples
[14, 28, 32, 48]. Previous studies on urinary arsenic excretion profiles demonstrated that there
are large variations among individual patients with regard to the arsenic metabolic profiles
and excretion patterns. For instance, an initial study demonstrated that urinary arsenic
contents slightly increased during drug administration and the total amounts of arsenic
excreted daily into the urine accounted for approximately 1–8% of the daily dose [14].
However, a previous report revealed that the mean total arsenic excretion rate including
inorganic arsenic and methylated arsenic was about 20% of the daily dose on day 1 and
remained at about 60% of the daily dose during subsequent weeks [28]. A clinical pharmaco‐
kinetic study performed in an APL patient showed that, in the urine sample collected for 24 h
after administration of ATO, the total amount of inorganic arsenic and the methylated
metabolites was almost 30% more of the daily dose [32]. Furthermore, Wang et al. [48] have
demonstrated that there is an interindividual difference in excretion profiles and the relative
concentrations of major arsenic species in the urine among four Chinese APL patients under‐
going ATO treatment. In addition, other pathways of excretion, such as through the bile, have
also been suggested to play a partial role in the elimination of arsenic [14, 48]. Therefore,
systematic monitoring of the speciation of arsenic compounds in not only urine samples but
also other biological samples such as the PB plasma has important implications for achieving
favorable outcomes and minimizing side effects in leukemia patients treated with arsenic-
based regimens.
2.5. Pharmacokinetic studies of realgar in leukemia patients as well as a healthy volunteer
Realgar has been widely used clinically in China [17, 18]. Moreover, an As2S2-containing
formula, Qinghuang powder (QHP), was used as a folk medicine recorded in a famous
traditional Chinese medicine (TCM) book, Shi Yi De Xiao Fang, published in 1345. Despite
this, the systematic study on metabolic profiles of realgar and its pharmacokinetics have not
yet been fully investigated. Compared with intravenous administration of ATO, oral admin‐
istration of realgar is advantageous and would be more suitable for consolidation and
maintenance therapy and consequently make better patient compliance and quality of life [16].
In this regard, Lu and colleagues designed a pilot study in which 129 APL patients with
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different disease stages were enrolled and received oral administration of highly purified
crystalline realgar (As4S4) [19]. In this pilot study, encouraging responses such as high complete
remission rate, long disease-free survival period, and tolerable side effects after oral adminis‐
tration of realgar alone were observed [19]. Furthermore, clinical pharmacokinetic studies on
seven volunteers with APL and hematologic complete remission (HCR) by using 60 mg/kg
oral As4S4 in a single dose demonstrated that arsenic could be detected in the blood 30 min
after oral administration of As4S4. The peak time (Tpeak) was 3.4 ± 1.4 h, and the maximum
concentration (Cmax) was 24.9 ± 8.0 μg/l. As expected, there was a wide interpatient variation
in area under the concentration–time curve (AUC0-infinity) (899.01 ± 705.64 μg/h per liter) and
elimination half-life (t1/2) (30.1 ± 11.1 h). These pharmacokinetic data revealed that rapid
absorption of arsenic occurred after oral administration of As4S4 [19]. In addition, most urinary
arsenic excretion occurred within the first 24 h. Measurement of blood arsenic levels in eight
patients who were given oral As4S4 at a dosage of 50 mg/kg/day for 2 weeks followed by a
break of 2 weeks during the first year of treatment demonstrated that blood arsenic levels
declined during the drug withdraw period [19]. Arsenic concentrations in plasma and red cells
were also measured in five patients with newly diagnosed APL and showed that the red-cell
arsenic level was approximately two times higher than the plasma level, similar to the findings
observed in an APL patient treated with ATO. Similar to the behavior of blood arsenic levels,
urinary arsenic levels also quickly declined after discontinuation of As4S4. Of note, the arsenic
level in the CSF in nine patients on the 10th day of treatment was 5.6–14.6 μg/l, a level similar
to that in plasma, indicated that oral As4S4 is capable of penetrating into the CSF, suggesting
the usefulness of As4S4 for the CNS relapse of APL [19]. These previous findings suggested
that As4S4 treatment alone is highly effective and safe in both remission induction and
maintenance therapy in patients with APL, regardless of disease stage.
Recently, the therapeutic effects of QHP have been evaluated in MDS patients with different
karyotypes, including normal karyotype, trisomy 8 karyotype, and other cytogenetic abnor‐
malities after receiving one to two 3-month courses of oral administration of QHP (containing
realgar 0.16 g/capsule/day). Furthermore, the PB samples were collected 10–12 h after inges‐
tion, and the total arsenic concentrations in the PB or PB plasma were determined using HPLC/
ICP-MS. A positive correlation was found between the efficacy of QHP and total arsenic
concentrations in the PB, but not in the PB plasma. Compared with patients with other
cytogenetic abnormalities, much better clinical efficacy was observed in patients with normal
or trisomy 8 karyotype, in agreement with our previous findings [49]. Surprisingly, no
significant difference in the total arsenic concentrations in the PB was observed between the
high-efficacy groups (patients with normal or trisomy 8 karyotype) and low-efficacy groups
(patients with other cytogenetic abnormalities). Furthermore, no correlation between total
arsenic concentrations in the PB or PB plasma and administration period was found in the
study, suggesting that realgar might have a relatively low absorption/accumulation rate.
Interestingly, compared with patients who did not receive oral administration of QHP, no
apparent alteration in the mitochondria membrane potential (ΔΨm) was found in primary
blasts from the BM in patients treated with QHP. Moreover, among 28 patients treated with
QHP, no correlation between ΔΨm and total arsenic concentrations in the PB was observed,
suggesting that the mitochondria might not be the main target for QHP, although further
detailed studies are obviously needed.
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Currently, as much as 49 items among approximately 500 TCMs contain realgar [16]. Further‐
more, there are 22 registered oral formulae containing realgar in the Chinese Pharmacopoeia
2010, which account for nearly 50% of the 49 realgar-containing formulae listed in the Phar‐
macopoeia [16]. Since TCM has been evolved and developed through long-term historical
clinical practice, many TCMs are available over the counter. However, the lack of scientific
evidence, especially in pharmacokinetics, results in a difficulty in its clinical application. In
this regard, Koch and colleagues investigated the bioaccessibility (a surrogate measurement
for bioavailability) and excretion of Niu Huang Jie Du Pain (translated as cow bezoar detoxifying
pills), one of the most commonly used over-the-counter TCMs containing about 7% of arsenic
in the form of realgar [50]. Analysis of the amount of arsenic available for absorption using
three different bioaccessibility methods demonstrated that, although the total arsenic exist as
high as 28 mg in a single pill, only 4% of it was available for absorption into the bloodstream
(1 mg of arsenic per pill), suggesting that the bioaccessibility of realgar is very poor [50]. In
fact, the poor bioaccessibility and/or bioavailability of realgar has also been reported by other
researchers [51, 52]. Therefore, these observations raise the possibility that mild toxicity of the
clinical application of realgar reported might be attributed to poor bioaccessibility and/or
bioavailability, rather than its low toxic nature. Obviously, in order to draw a firm conclusion,
more detailed studies are needed.
Koch and colleagues also evaluated arsenic concentrations and their speciation in urinary
samples collected from a volunteer aged 70 years before and after ingestion of one pill of Niu
Huang Jie Du Pain. [50]. The maximum value of the total arsenic species excreted after the
ingestion of the one pill appeared approximately 14 h after ingestion, and methylated arsenic
metabolites (MAsV and DMAsV) were the predominant species. The proportion of methylated
arsenic metabolites in all arsenical species are in total agreement with previous arsenic
metabolic profiles observed in other clinical samples, including the PB plasma, the CSF, and
BM obtained from APL patients undergoing ATO treatment [4, 29–31], and healthy individuals
who have drunk water containing inorganic arsenic [26, 27], reconfirming that biomethylation
is a major detoxification pathway for inorganic arsenicals, regardless of different forms of
arsenic. Interestingly, compared with previous findings showing that MAsIII and DMAsIII have
been detected in the urine of APL patients undergoing ATO treatment [48] and healthy
individuals who have drunk water containing inorganic arsenic [25, 53], no traces of MAsIII
and DMAsIII were detected in the urine collected at any time after ingestion of one pill of Niu
Huang Jie Du Pain, although two different HPLC/ICP-MS conditions, which were certified as
the optimal condition for distinguishing MAsIII and DMAsIII from other arsenic species, were
used [50]. It is important to note that there should be some differences in metabolic profiles
between taking a single dose or multiple doses. Since the aforementioned sampling of the urine
was from a single individual who just took only one dose of Niu Huang Jie Du Pain, further
research is desirable to study the more realistic exposure of multiple chronic doses, as well as
to include more individuals to gain more statistical strength for populations consuming these
medicines [50].
Due to the poor bioaccessibility and/or bioavailability of realgar mentioned above, realgar
nanoparticles (NPs) were designed to improve its pharmacological and toxicological profiles
[16]. It has been demonstrated that, compared with commercially used coarse realgar powder,
realgar NPs with a size less than 200 nm prepared even by different methods show much higher
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efficiency in cytotoxicity associated with apoptosis induction and differentiation induction in
leukemic cells such as HL-60 and U937 [54–57]. Although the detailed pharmacokinetic studies
on realgar NPs have not yet been investigated in human beings, an in vivo bioavailability of
realgar NPs prepared by cryo-grinding with polyvinylpyrrolidone (PVP) and/or SDS was
evaluated in rats [58]. In this study, a remarkable increase in the urinary recovery of arsenic
was observed in rats after a single oral administration of the cryo-ground realgar particle
suspension. A range of 58.5–69.6% of the administered dose of arsenic was recovered in urine
in the first 48 h from the PVP and/or SDS co-ground preparations; whereas the original realgar
powder gave a urinary recovery of only 24.9%, suggesting that size reduction of realgar
particles to nano levels could substantially enhance their bioavailability [58]. Furthermore, the
cytotoxicity of the realgar NPs to human gynecological cell lines such as GI80-13S, Hela cells
was comparable with the ATO observed previously [58]. Interestingly, realgar NPs were also
found to be successfully delivered by transdermal administration, which gave more thera‐
peutic efficiency than intraperitoneal administration in a model of treating melanoma skin
tumor-bearing C57BL/6 mice, raising the possibility of its new clinical use [59].
It is well known that, besides administration of arsenic to patients in clinical practice, arsenic
can also enter the body through food chains. The most common exposure to high levels of
arsenic in food is through marine products in the form of arsenobetaine or plant products in
the form of various arsenosugars [4]. Arsenobetaine, a trimethylarsenic compound, is one of
the major organic arsenic in seafood and is not produced by the metabolism of AsIII in human
[34, 60]. Once arsenobetaine is ingested during periods of arsenic-based therapy, it will be
excreted from the body in the same form and consequently interrupt the accuracy of evaluation
of the pharmacokinetics of arsenic species. Therefore, controlling the daily diet, in particular
seafood, during the periods of remission induction therapy and/or consolidation therapy is
very important to accurately monitor the metabolic profiles of arsenic.
3. Mechanisms underlying the cytocidal effects of arsenic compounds
3.1. Involvement of oxidative stress in arsenic-mediated apoptosis induction
The remarkable clinical results achieved with ATO and realgar in relapsed as well as newly
diagnosed APL patients have promoted investigations to determine the mechanisms under‐
lying their activity. Accumulating evidence has shown that ATO exerts dose-dependent dual
effects in APL cells such as NB4, with preferential apoptosis at relatively high concentrations
ranging from 0.5 μM to 2.0 μM and partial differentiation at relatively low concentrations
ranging from 0.1 to 0.5 μM [4, 61, 62]. The apoptosis-inducing effect is primarily associated
with the mitochondrial-mediated intrinsic apoptotic pathway, whereas the extrinsic pathway
through death receptors, such as the tumor necrosis factor receptor (TNFR) and Fas, have also
been reported to be implicated in ATO-induced apoptosis in human leukemia, lymphoma, as
well as glioma cell lines [63–65]. Moreover, a third pathway involving endoplasmic reticulum
and caspase-12 has been reported to associate with ATO-mediated apoptosis in the chronic
myeloid leukemia cell line K562 [66].
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It has become clear that oxidative damage is one of the main mechanisms by which arsenic
induces apoptosis [4, 6, 55, 61, 62, 67]. This idea is consistent with the binding capacity of
arsenite to adjacent sulfhydryl (SH) groups present in many vital biomolecules [4, 6, 61, 62,
67] and also strongly supported by clinical data that levels of 8-hydroxy-2’-deoxyguanosine
(8-OH-dGuo), one of the most abundant oxidative products of DNA, are increased in plasma
from APL patients after remission induction and consolidation therapy with ATO [68]. Similar
to ATO, realgar NPs also caused elevated urinary 8-OH-dGuo excretion in rats from day 1
after oral administration [69]. ATO has been demonstrated to disrupt mitochondrial respira‐
tion through blockading of electron flow at complex III and IV to elevate the generation of
oxygen free radicals [70]. It has also been reported that reduced nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase-derived reactive oxygen species (ROS) are respon‐
sible for the susceptibility to arsenic cytotoxicity in leukemia cells [71, 72]. Furthermore,
downregulation of the ROS elimination system, comprising glutathione (GSH), thioredoxin,
and anti-oxidative enzymes including superoxide dismutase (SOD), catalase, as well as
glutathione peroxidase (GPx), has been reported to be involved in cytocidal effects of arsenic
compounds [73–78]. In line with these findings, GPx inhibitors such as mercaptosuccinic acid
[79], catalase inhibitors such as 3-amino-1,2,4-trizaole [79], and SOD inhibitors such as 2-
methoxyestradiol have been reported to potentiate the apoptosis-inducing activity of arsenic
in NB4 cells as well as primary leukemia cells from patients with chronic lymphocytic leukemia
[70, 73, 80]. Collectively, through not only enhancing the ROS production system but also
impairing the ROS elimination system, arsenic compounds are able to induce intracellular ROS
accumulation, which, in turn, activates apoptotic pathways in hematological cell lines
including the APL cell line [41, 73, 74, 81–84].
3.2. Differentiation induction
In vitro and in vivo studies have demonstrated that a low-dose of ATO (0.1 ~ 0.5 μM) induces
differentiation of NB4, a human APL cell line with t(15;17), as well as fresh APL cells [15, 81,
85]. Morphological changes such as condensation of chromatin, lobulation of nuclei, and the
expression profiling of surface markers have been used as markers of the differentiation of
APL cells [15, 81, 85]. Consistent with previous findings, we have recently demonstrated that
0.125 μM ATO also induced differentiation in HT93A cells, another t(15;17)-positive APL cell
line established from the peripheral blood of a patient with APL [86], as evidenced by the
appearance of jelly-bean-shaped nuclei in almost all cells, accompanied by a significant
increase in CD11c and CD15 expression [87]. Furthermore, we demonstrated that As2S2
induced granulocyte differentiation in HL-60 cells, as evidenced by the increment in CD11b
expression, in which oxidative stress associated with GSH depletion and p38 mitogen-
activated protein kinase (MAPK) activation was involved [77, 84]. More interestingly, we have
recently found that treatment with As2S2 induced erythroid differentiation in F36p, derived
from MDS/AML, and HL-60 cells, as evidenced by a dose-dependent increase in the expression
level of CD235a, a marker for the detection of the erythroid cell lineage [88, 89]. We further
demonstrated that, although the alteration in the expression level of phosphorylated and total
p38 MAPK was observed to some extent in parallel with As2S2-induced erythroid differentia‐
tion, no alteration was observed in the expression level of CD235a, regardless of the presence
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or absence of SB203580, a specific inhibitor for p38 MAPK, suggesting that p38 MAPK plays a
small role in As2S2-induced erythroid differentiation in HL-60 cells [89]. Therefore, our findings
suggest that p38 MAPK plays a critical role in As2S2-induced differentiation into granulocytes,
rather than erythroid differentiation.
It has been demonstrated that higher DNA methylation levels at a few CpG sites in some
erythroid specific genes correlated with a decreased erythroid differentiation capacity of K562
cells, which has been proposed as a very useful in vitro model system for studying erythroid
differentiation [90, 91]. We have recently evaluate the effects of the As2S2-containing Chinese
herbal formula QHP on the genomic methylation level in primarily diagnosed MDS patients
[49], since MDS patients, especially those with high-risk MDS, have been reported to possess
abnormal hypermethylation in tumor suppressor genes [92]. In this study, global DNA
methylation detection (ChIP-on-chip assays) demonstrated that the number of hypermethy‐
lated genes decreased from 1,063 to 75 and that the methylated genes involved in multicellular
organismal development, signal transduction, and apoptosis were demethylated after
treatment with QHP [49]. We thus suggest that demethylation status, which might be resulted
from As2S2 treatment, attributed to the above-mentioned erythroid differentiation of F36 and
HL-60 cells, although further investigation of a correlation between erythroid differentiation
and As2S2-triggered demethylation in these cells is needed to draw a more conclusive idea.
Collectively, our findings provide a conceptual basis for the establishment of clinical protocols
of As2S2 for the treatment of hematological disorders, in particular MDS and MDS/AML.
3.3. Degradation of PML-RARα
It is no doubt that PML-RARα plays a central role in the initiation of leukemogenesis, although
there is evidence to suggest that the fusion gene expression is not the sole genetic event
required for the development of APL [4–6]. It has been clarified that arsenic-mediated
modulation/degradation of the PML-RARα oncoprotein is one of the major mechanisms
responsible for the efficacy of arsenic compounds in APL [4–6, 93]. Furthermore, the PML
moiety, but not the RARα moiety, of the PML-RARα chimera represents the target for arsenic
treatment [6, 61]. It has been clarified that both PML and PML-RARα form high-molecular-
weight conjugates with a small ubiquitin-related modifier (SUMO)-1 and are recruited from
the nucleoplasm to the nuclear body (NB), followed by ubiquitin-mediated proteolysis [94–
96]. Degradation of PML-RARα is closely associated with differentiation, growth inhibition
associated with the induction of apoptosis, as well as cell cycle arrest in APL cells treated with
arsenic compounds [4–6, 93]. In addition, degradation of the PML-RARα protein associated
with its redistribution was also reported in fresh APL cells obtained from the PB and BM of
APL patients after treatment with As4S4 [97]. More intriguingly, Tian and colleagues have
recently investigated the effects of As4S4 on RA-resistant human APL NB4-R1 cells and found
that treatment with As4S4 induced apoptosis in cells through the downregulation of expression
of the SET gene, which is a natural inhibitor for protein phosphatase 2 (PP2A), a pro-apoptotic
protein [93]. They further demonstrated that the addition of As4S4 strengthened the SET RNAi-
induced upregulation of PP2A and the downregulation of PML-RARα, suggesting that As4S4
induces apoptosis through the downregulation of the SET protein expression, which, in turn,
increases PP2A expression and reduces PML-RARα expression, consequently leading to the
apoptosis of NB4-R1 cells [93].
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4. Potential combination therapies with arsenic compounds
An extensive body of literature has clearly demonstrated superiority in treating APL simul‐
taneously with ATO and ATRA [4–6, 61, 98]. It has been demonstrated that ATRA synergizes
ATO activity to provide superior efficacy of combination therapy in patients by promoting the
effects of ATO on several signaling pathways such as apoptosis induction, differentiation, as
well as the degradation of PML-RARα [4–6]. In this regard, we have recently investigated the
effects of ATO, ATRA, and the granulocyte colony-stimulating factor (G-CSF), alone or in
combination, on the APL cell line HT93A by focusing on differentiation, growth inhibition, as
well as arsenic uptake [87]. Our experimental data demonstrated that ATRA induced greater
differentiation in cells than ATO and that G-CSF promoted differentiation-inducing activities
of both ATO and ATRA [87]. Similar to a previous report showing that ATRA induced
aquaporin-9 (AQP-9), which is a member of the aquaporin superfamily and proposed to be
responsible for arsenic uptake [99–101], in HL-60 cells, we also demonstrated that ATRA
induced AQP9 expression in a time- and dose-dependent manner in HT93A cells [87].
However, probably due to its cytotoxicity, treatment with 1 μM ATRA decreased arsenic
uptake compared with the control subject. Interestingly, the addition of G-CSF recovered the
reduced arsenic uptake to the same level as that in controls by increasing the number of viable
cells, although G-CSF itself did not affect the expression levels of AQP9 [87]. Collectively, our
results indicate that G-CSF not only promotes differentiation-inducing activities of both ATRA
and ATO but also makes APL cells vulnerable to increased arsenic uptake, providing new
insight into combination therapy using these three agents for the treatment of APL.
Since HDACs play a key role in the transcriptional regulation and pathogenesis of cancer [102,
103], its inhibitors (HDACi) are currently being developed for the therapy of several types of
cancer, including leukemia [104]. Furthermore, aberrant recruitment of HDACs through the
expression of PML-RARα has been implicated as an initiating tumorigenic event in APL [5–
7]. Based on these previous findings, we hypothesized that treatment with ATRA in combi‐
nation with HDACi could provide therapeutic benefit for patients with APL. In this regard,
we investigated the effects of ATRA and valproic acid (VPA), alone and in combination, on
the NB4 cells in view of differentiation induction and growth inhibition [105], since VPA is a
member of class I HDACi and has shown potential anti-leukemic activities either alone or in
combination with other anti-leukemic agents [102, 103, 106, 107]. In this study, we demon‐
strated that not only ATRA but also VPA induced differentiation in NB4 cells, and their
combination further augmented the differentiation activity [105]. We further demonstrated
that the upregulation of transcription factors, including CCAAT/enhancer-binding proteins
(CEBPα, β, ε) and PU.1, which are known to be critical factors for normal myelopoiesis,
granulocytic maturation, and being repressed in APL, concurred with the differentiation
induction [105]. Given the importance of CEBPs and PU.1 in myeloid development, our results
thus suggest that restoration of the normal function of the myeloid cell transcriptional
machinery is a major molecular mechanism underlying the differentiation induction in NB4
cells [105]. It has been suggested that ATO/ATRA degrades the PML-RARα oncoprotein,
resulting in the eradication of leukemia-initiating cells [108, 109]. Therefore, as a new thera‐
peutic approach, a multi-target therapy based on a combination of ATRA, ATO, and VPA
would be useful and worth evaluating further for its beneficial clinical effects.
Perspective on Therapeutic Strategies of Leukemia Treatment — Focus on Arsenic Compounds
http://dx.doi.org/10.5772/60786
203
Although advances in science and technology have replaced raw herbs and/or herbal com‐
pounds with powerful synthetic drugs, including molecular target-based drugs, in cancer
therapy, the issue of concern is still resistance, disease relapse, and side effects of drugs in a
clinical setting. In the case of arsenic compounds, side effects such as white blood cell count,
QT prolongation, as well as liver dysfunction are still a serious concern and limit further clinical
application, although the remarkable clinical efficacy of arsenic compound-based regimens
against APL has been reported [4, 16]. Therefore, application of new arsenic-based therapies
may require the generation of sensitizing strategies for improving the efficacy of arsenic
compounds as well as minimizing their side effects. In order to optimize and/or maximize
future clinical applications of arsenic compounds in patients with leukemia or even other
malignancies, including solid tumors, combination therapy has attracted considerable interest
as new therapeutic strategies. In this regard, we have been interested in the effects of naturally
derived substances such as flavonoids on different kinds of cancerous cells, including leukemic
cells [110–115]. Of these, Vitex, an extract from the ripe fruit of Vitex agnus-castus, has attracted
great attention [112, 113, 115, 116]. We have investigated the effects of Vitex and its major
component, casticin (Figure 2), on leukemia cell lines, HL-60 and U-937, and found that HL-60
cells were more sensitive to the cytotoxicity of Vitex/casticin compared with U-937 cells [112].
Furthermore, compared with unstimulated HL-60 cells, phorbol 12-myristate 13-acetate
(PMA)- and 1,25-dihydroxyvitamin D3 (VD3)-differentiated HL-60 cells acquired resistance
to Vitex/casticin. Based on the observation that the HL-60 cell line is more immature than the
U-937 cell line, our results suggest that the levels of cytotoxicity of Vitex/casticin were largely
attributed to the degree of differentiation of leukemia cells; that is, cell lines with less differ‐
entiated phenotype were more susceptible than the differentiated ones [112]. More impor‐
tantly, much less cytotoxicity was observed in peripheral blood mononuclear cells (PBMNCs)
from healthy volunteers when treated with concentrations of Vitex/casticin showing signifi‐
cant cytotoxicity in both leukemic cell lines [112]. Since recent studies have demonstrated that
less differentiated cancer cells, referred to as leukemia stem cells (LSCs), acquired limitless
self-renewal through oncogenic transformation and that the incomplete eradication of primary
LSCs is closely linked to chemotherapy resistance and consequently contribute to eventual
disease relapse [117], our findings thus provide fundamental insight into the clinical applica‐
tion of Vitex/casticin for hematopoietic malignancy in combination with arsenic compounds.
We further demonstrated [113, 114] that Vitex/casticin-triggered cytotoxicity in HL-60 cells
was implicated in histone H3 phosphorylation through the activation of the p38 MAPK
pathway, which is a common signaling pathway involved in the mechanism underlying the
cytocidal effects of arsenic compounds [4, 6, 16]. These findings suggest that Vitex/casticin
could be promising candidates of adjunct therapeutic reagents for leukemia patients.
Delphinidin (Figure 2), a major anthocyanidin known to be present in pigmented fruits and
vegetables, such as pomegranate, berries, dark grapes, eggplant, and red onion, is a diphe‐
nylpropane-based polyphenolic ring structure that carries a positive charge in its central ring
[118]. Delphinidin has been gaining considerable attention, as it appears to possess a strong
antioxidant/oxidant property as well as other potentially beneficial traits, such as anti-
inflammatory, antimutagenesis, and antiangiogenesis activities [119, 120]. Furthermore,
delphinidin and its glycosides have been demonstrated to trigger apoptosis in HL-60 cells
Leukemias - Updates and New Insights204
through a ROS/JNK-mediated mitochondrial death pathway [121, 122]. We have recently
demonstrated that delphinidin exhibited a dose- and time-dependent cytotoxic effect against
NB4 cells, in which intrinsic/extrinsic pathway-mediated apoptosis, but not cell cycle arrest,
was involved (Yuan et al, submitted). We further demonstrated that delphinidin exerted more
potent cytotoxicity against NB4 cells than normal PBMNCs and that delphinidin in combina‐
tion with arsenite achieved an enhanced cytocidal effect against NB4 cells, but lesser on
PBMNCs (Yuan et al, submitted). These results suggest that delphinidin selectively sensitizes
NB4 cells to arsenite, resulting in an enhancement of arsenite cytotoxicity by strengthening
intrinsic/extrinsic pathway-mediated apoptosis induction. Our observations may offer a
rationale for the use of delphinidin to improve the clinical efficacy of arsenite.
Intriguingly, it has been revealed that flavonoids can inhibit the function of ATP-binding
cassette transporters such as multidrug-resistance-associated proteins (MRPs) as well as P-
glycoprotein (P-gp) [123, 124], which are known to be responsible for the efflux of arsenic and
may consequently contribute to resistance to arsenic therapy [4, 125, 126]. In addition, we have
recently demonstrated [101] that MRP2 and AQP9, which belongs to the aquaporin super‐
family and is closely associated with arsenic uptake, contribute to the differential sensitivity
of primary human-derived normal cells to arsenite using a unique in vitro primary cell culture
system [79, 127, 128]. Therefore, the influence of naturally derived substances on the expression
of transporters associated with intracellular arsenic accumulation should be taken into account
during treatment in combination with arsenic compounds. More recently, by using human
embryonic kidney epithelial (HEK) 293 cells overexpressing MRP4 cells, we have demonstrat‐
ed (Yuan et al., manuscript in preparation) that MRP4, another member of ABC transporters,
could be one of the major contributors to arsenic resistance, although further investigation into
the correlation between the expression status of MRP4 and the treatment outcome of leukemia
patients treated with arsenic-based regimens is needed.
In traditional medicines, including TCM, formulae consisting of more than one active ingre‐
dients are actually much more frequently used, aiming to act on more than one pharmacolog‐
 
 
Figure 2. Chemical structures of casticin and delphinidin.
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ical targets and thus exerting synergistic therapeutic effects. One of the most successful models
is the realgar–indigo naturalis formula (RIF), in which arsenic sulfide (A), indirubin (I), and
tanshinone IIA (T) are three major components, and has been found effective against APL in
China [16]. In this regard, Wang and colleagues performed the dissection of mechanisms of
RIF using an APL murine model and APL cells, including NB4, NB4-R2 (ATRA-resistant NB4-
derived cell lines), and primary leukemic cells from APL patients [129]. Their results not only
indicated the functions of each component, e.g., A acted as a principal component, whereas I
and T served as adjuvant ones, but also demonstrated the generation of expected synergistic
effects in view of prolongation of the life span of treated mice, the efficiency of terminal
differentiation induction, and the upregulation of APQ9 expression associated with increment
in intracellular arsenic accumulation, without apparent severe side effects [129]. This study
provides new insight into exploring the value of traditional formulae on a larger scale and
helping to bridge Western and Eastern medicines in the era of systems biology. Besides, we
also focused on the effects of products derived from the human body, such as progesterone
(Pg), and demonstrated that Pg induced a dose- and time-dependent cell growth inhibition in
A3 and I9.2 cells, both of which are subclones of a T-cell-derived leukemic Jurkat cell line [130].
We further suggested that growth suppression accompanied with the induction of apoptosis
by Pg in these cells was mediated through the mitochondrial membrane disruption, followed
by the activation of the caspase cascade [130]. These results provide a novel insight into Pg
actions toward its use for clinical application in patients with lymphocytic T-cell leukemia and
raise the possibility of combination with arsenic compounds.
5. Conclusions
A striking global in vivo and in vitro study on the treatment with arsenic compounds, alone or
in combination, is being explored to understand detailed mechanisms underlying their
efficiency in not only APL but also many other malignancies, including arsenic-resistant
hematopoietic cancer or even solid tumors. Due to the higher reactivity and instability of
trivalent methyl arsenic metabolites such as MAsIII and DMAsIII, a more accurate assessment
of these metabolites in biological samples such as blood still need to be improved, although
some preservatives, including diethyldithiocarbomate [48] and 2,3-dimercaptopropanesulph‐
onate [131], have been used to stabilize these metabolites in urine samples. As mentioned
above, considerable amounts of arsenic species exist in clinical samples as a protein-bound
complex. Although analysis of these protein-bound arsenic complexes has been conducted,
the losses of these complexes from the sampling to the detection stage have not yet been
resolved [131]. Therefore, the development of more applicable contemporary analytical
protocols for these unstable arsenic species shall be explored. Furthermore, in order to achieve
better therapeutic effects for individual APL patients and reduce side effects of arsenic
compounds, not only detailed arsenic biomonitoring but also a predictive molecular biomarker
for arsenic therapy is greatly desired. In this regard, we have recently investigated the
correlation between the expression levels of AQP9 and sensitivity to ATO using NB4, HT93A,
as well as primary APL cells from newly diagnosed and relapsed APL patients and provided
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direct evidence that the expression of AQP9, rather than other biomarkers such as cell surface
markers and chromosomal alteration, closely correlate with the sensitivity to ATO in both APL
cell lines and primary blasts [132]. Our findings thus suggest that the AQP9 expression status
of APL patients is a predictive marker for the successful outcome of ATO treatment. At the
same time, we also showed that flow cytometry may be a new convenient and valuable tool
for analyzing the AQP9 status of APL patients compared with current methods such as
Western blotting [132]. Many naturally derived substances, including TCM, have been shown
to be promising candidates endowed with potent antitumor activities in view of combination
with arsenic compounds. In fact, many patients in Asian countries, especially those with end-
stage cancer, prefer to choose traditional medicine therapy alone or in combination with
chemotherapy, radiation therapy, as well as targeted therapy, aimed to palliate symptoms and
improve the quality of life. Therefore, besides efforts in exploring the detailed molecular
mechanism underlying their cytocidal effects against cancerous cells, systematic analyses
aimed at understanding the pharmacology and toxicology profiles are eagerly awaited when
used alone or in combination with other clinical drugs such arsenic compounds.
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